The Fetal Safety of Enoxaparin Use During Pregnancy: A Population-Based Retrospective Cohort Study

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2017 Jul 23

PMID 28733971

Citations 4

Authors

Meital Shlomo

Rafael Gorodischer

Sharon Daniel

Arnon Wiznitzer

Ilan Matok

Boris Fishman

Gideon Koren

Amalia Levy

Affiliations

Soon will be listed here.

Abstract

Introduction: Enoxaparin is widely used during pregnancy as pregnancy is a hypercoagulable state; however, its fetal safety has scarcely been investigated.

Objective: Our study aimed to examine fetal safety following enoxaparin exposure during pregnancy.

Methods: A population-based, retrospective cohort study was performed by linking computerized databases, including the drug dispensing registries of Clalit Health Services in Israel and maternal and infant hospital records, between 1998 and 2009. Multivariate logistic regression models were used to examine associations between first- and third-trimester exposure to enoxaparin, major malformations, and other adverse birth outcomes, adjusted for confounders.

Results: From a total of 109,473 singleton pregnancies, 418 and 572 were exposed to enoxaparin during the first and third trimesters, respectively. Exposure to enoxaparin during the first trimester of pregnancy was not associated with an increased risk of major congenital malformations [adjusted odds ratio (aOR) 1.1, 95% confidence interval (CI) 0.8-1.6], while exposure during the third trimester was not associated with an increased risk of low birth weight (aOR 1.1, 95% CI 0.8-1.4), low Apgar score (aOR 0.9, 95% CI 0.4-1.8), or risk of perinatal mortality (aOR 0.6, 95% CI 0.1-2.9).

Conclusion: Exposure to enoxaparin during pregnancy was not associated with an increased risk of major malformations in general or according to organ systems. Nonetheless, risk for specific malformations cannot be ruled out.

Citing Articles

Available medications used as potential therapeutics for COVID-19: What are the known safety profiles in pregnancy.

Berard A, Sheehy O, Zhao J, Vinet E, Quach C, Kassai B PLoS One. 2021; 16(5):e0251746.

PMID: 34010282 PMC: 8133446. DOI: 10.1371/journal.pone.0251746.

COVID-19, Virchow's triad and thromboembolic risk in obese pregnant women.

Carbillon L, Fermaut M, Benbara A, Boujenah J Clin Cardiol. 2021; 44(5):593-594.

PMID: 33760245 PMC: 8119852. DOI: 10.1002/clc.23602.

Risk factors for congenital heart disease: The Baby Hearts Study, a population-based case-control study.

Dolk H, McCullough N, Callaghan S, Casey F, Craig B, Given J PLoS One. 2020; 15(2):e0227908.

PMID: 32092068 PMC: 7039413. DOI: 10.1371/journal.pone.0227908.

Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.

Jacobson B, Rambiritch V, Paek D, Sayre T, Naidoo P, Shan J Adv Ther. 2019; 37(1):27-40.

PMID: 31673991 PMC: 6979442. DOI: 10.1007/s12325-019-01124-z.

References

West S, Savitz D, Koch G, Strom B, Guess H, Hartzema A . Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995; 142(10):1103-12. DOI: 10.1093/oxfordjournals.aje.a117563. View

Reece E, Gabrielli S, Cullen M, Zheng X, Hobbins J, Harris E . Recurrent adverse pregnancy outcome and antiphospholipid antibodies. Am J Obstet Gynecol. 1990; 163(1 Pt 1):162-9. DOI: 10.1016/s0002-9378(11)90692-9. View

Badawy A, Khiary M, Sherif L, Hassan M, Ragab A, Abdelall I . Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol. 2008; 28(3):280-4. DOI: 10.1080/01443610802042688. View

Johnson R, Vollmer W . Comparing sources of drug data about the elderly. J Am Geriatr Soc. 1991; 39(11):1079-84. DOI: 10.1111/j.1532-5415.1991.tb02872.x. View

. Investigation and management of heritable thrombophilia. Br J Haematol. 2001; 114(3):512-28. DOI: 10.1046/j.1365-2141.2001.02981.x. View

Sheiner E, Shoham-Vardi I, Weitzman D, Gohar J, Carmi R . Decisions regarding pregnancy termination among Bedouin couples referred to third level ultrasound clinic. Eur J Obstet Gynecol Reprod Biol. 1998; 76(2):141-6. DOI: 10.1016/s0301-2115(97)00178-4. View

Lepercq J, Conard J, Borel-Derlon A, Darmon J, Boudignat O, Francoual C . Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG. 2002; 108(11):1134-40. DOI: 10.1111/j.1471-0528.2003.00272.x. View

de Jong van den Berg L, Feenstra N, Sorensen H, Cornel M . Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. Teratology. 1999; 60(1):33-6. DOI: 10.1002/(SICI)1096-9926(199907)60:1<33::AID-TERA9>3.0.CO;2-X. View

Ray W, Griffin M . Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol. 1989; 129(4):837-49. DOI: 10.1093/oxfordjournals.aje.a115198. View

10.

Gris J, Chauleur C, Faillie J, Baer G, Mares P, Fabbro-Peray P . Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost. 2010; 104(4):771-9. DOI: 10.1160/TH10-03-0167. View

11.

Heit J, Spencer F, White R . The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016; 41(1):3-14. PMC: 4715842. DOI: 10.1007/s11239-015-1311-6. View

12.

Greer I, Nelson-Piercy C . Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005; 106(2):401-7. DOI: 10.1182/blood-2005-02-0626. View

13.

Ginsberg J, Hirsh J, Turner D, Levine M, Burrows R . Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost. 1989; 61(2):197-203. View

14.

Sheiner E, Shoham-Vardi I, Sheiner E, Mazor M, Katz M, Carmi R . Maternal factors associated with severity of birth defects. Int J Gynaecol Obstet. 1999; 64(3):227-32. DOI: 10.1016/s0020-7292(98)00166-0. View

15.

Brenner B . Haemostatic changes in pregnancy. Thromb Res. 2004; 114(5-6):409-14. DOI: 10.1016/j.thromres.2004.08.004. View

16.

Gris J, Chauleur C, Molinari N, Mares P, Fabbro-Peray P, Quere I . Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost. 2011; 106(6):1053-61. DOI: 10.1160/TH11-05-0340. View

17.

Alvarez A, Balcazar N, San Martin S, Markert U, Cadavid A . Modulation of antiphospholipid antibodies-induced trophoblast damage by different drugs used to prevent pregnancy morbidity associated with antiphospholipid syndrome. Am J Reprod Immunol. 2017; 77(4). DOI: 10.1111/aji.12634. View

18.

Heit J, Kobbervig C, James A, Petterson T, Bailey K, Melton 3rd L . Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005; 143(10):697-706. DOI: 10.7326/0003-4819-143-10-200511150-00006. View

19.

Branch D, Andres R, Digre K, Rote N, Scott J . The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol. 1989; 73(4):541-5. View

20.

Hall J, Pauli R, Wilson K . Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980; 68(1):122-40. DOI: 10.1016/0002-9343(80)90181-3. View